JP2023096009A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2023096009A5 JP2023096009A5 JP2023080165A JP2023080165A JP2023096009A5 JP 2023096009 A5 JP2023096009 A5 JP 2023096009A5 JP 2023080165 A JP2023080165 A JP 2023080165A JP 2023080165 A JP2023080165 A JP 2023080165A JP 2023096009 A5 JP2023096009 A5 JP 2023096009A5
- Authority
- JP
- Japan
- Prior art keywords
- double
- stranded
- pharmaceutical composition
- sequence
- molecule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025034711A JP2025093992A (ja) | 2018-02-21 | 2025-03-05 | 変異Ｐ５３特異的ｓｉＲＮＡを使用した標的癌治療 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SG10201801432S | 2018-02-21 | ||
| SG10201801432S | 2018-02-21 | ||
| JP2020544431A JP2021514195A (ja) | 2018-02-21 | 2019-02-21 | 変異Ｐ５３特異的ｓｉＲＮＡを使用した標的癌治療 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020544431A Division JP2021514195A (ja) | 2018-02-21 | 2019-02-21 | 変異Ｐ５３特異的ｓｉＲＮＡを使用した標的癌治療 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025034711A Division JP2025093992A (ja) | 2018-02-21 | 2025-03-05 | 変異Ｐ５３特異的ｓｉＲＮＡを使用した標的癌治療 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023096009A JP2023096009A (ja) | 2023-07-06 |
| JP2023096009A5 true JP2023096009A5 (enExample) | 2024-03-22 |
| JP7648675B2 JP7648675B2 (ja) | 2025-03-18 |
Family
ID=67687981
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020544431A Pending JP2021514195A (ja) | 2018-02-21 | 2019-02-21 | 変異Ｐ５３特異的ｓｉＲＮＡを使用した標的癌治療 |
| JP2023080165A Active JP7648675B2 (ja) | 2018-02-21 | 2023-05-15 | 変異Ｐ５３特異的ｓｉＲＮＡを使用した標的癌治療 |
| JP2025034711A Pending JP2025093992A (ja) | 2018-02-21 | 2025-03-05 | 変異Ｐ５３特異的ｓｉＲＮＡを使用した標的癌治療 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020544431A Pending JP2021514195A (ja) | 2018-02-21 | 2019-02-21 | 変異Ｐ５３特異的ｓｉＲＮＡを使用した標的癌治療 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025034711A Pending JP2025093992A (ja) | 2018-02-21 | 2025-03-05 | 変異Ｐ５３特異的ｓｉＲＮＡを使用した標的癌治療 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US12508277B2 (enExample) |
| EP (1) | EP3755802A4 (enExample) |
| JP (3) | JP2021514195A (enExample) |
| KR (1) | KR102741498B1 (enExample) |
| CN (1) | CN111727254B (enExample) |
| CA (1) | CA3090220A1 (enExample) |
| SG (1) | SG11202007450XA (enExample) |
| WO (1) | WO2019164451A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3090220A1 (en) | 2018-02-21 | 2019-08-29 | Singapore Health Services Pte Ltd | Cancer therapeutic targeting using mutant p53-specific sirnas |
| EP4077370A4 (en) * | 2019-12-17 | 2024-02-28 | The Johns Hopkins University | MANA BODY TARGETING TUMOR ANTIGENS AND METHODS OF USE |
| CN115820636B (zh) * | 2022-09-02 | 2024-06-11 | 华南农业大学 | 靶向TP53基因的sgRNA及其应用 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2832154B1 (fr) * | 2001-11-09 | 2007-03-16 | Centre Nat Rech Scient | Oligonucleotides inhibiteurs et leur utilisation pour reprimer specifiquement un gene |
| CA3090220A1 (en) | 2018-02-21 | 2019-08-29 | Singapore Health Services Pte Ltd | Cancer therapeutic targeting using mutant p53-specific sirnas |
-
2019
- 2019-02-21 CA CA3090220A patent/CA3090220A1/en active Pending
- 2019-02-21 EP EP19758146.5A patent/EP3755802A4/en active Pending
- 2019-02-21 WO PCT/SG2019/050099 patent/WO2019164451A1/en not_active Ceased
- 2019-02-21 JP JP2020544431A patent/JP2021514195A/ja active Pending
- 2019-02-21 CN CN201980013819.2A patent/CN111727254B/zh active Active
- 2019-02-21 US US16/971,626 patent/US12508277B2/en active Active
- 2019-02-21 SG SG11202007450XA patent/SG11202007450XA/en unknown
- 2019-02-21 KR KR1020207026511A patent/KR102741498B1/ko active Active
-
2023
- 2023-05-15 JP JP2023080165A patent/JP7648675B2/ja active Active
-
2025
- 2025-03-05 JP JP2025034711A patent/JP2025093992A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023096009A5 (enExample) | ||
| Zhang et al. | The roles of ZEB1 in tumorigenic progression and epigenetic modifications | |
| Mao et al. | Exosomal miR-141 promotes tumor angiogenesis via KLF12 in small cell lung cancer | |
| Jeon et al. | Combining microRNA-449a/b with a HDAC inhibitor has a synergistic effect on growth arrest in lung cancer | |
| Potenza et al. | MicroRNA‐125a‐5p is a downstream effector of sorafenib in its antiproliferative activity toward human hepatocellular carcinoma cells | |
| Malek et al. | Modulation of the activity of Sp transcription factors by mithramycin analogues as a new strategy for treatment of metastatic prostate cancer | |
| RU2017126601A (ru) | Способы и композиции для лечения злокачественных опухолей, ассоциированных с мутацией kras | |
| Zhang et al. | Deactivation of signal transducer and activator of transcription 3 reverses chemotherapeutics resistance of leukemia cells via down-regulating P-gp | |
| JP2010514787A5 (enExample) | ||
| Ramezankhani et al. | Novel molecular targets in gastric adenocarcinoma | |
| TWI855246B (zh) | 使用腫瘤治療電場（tt電場）之組合治療 | |
| Liu et al. | Glioblastoma tumor initiating cells: therapeutic strategies targeting apoptosis and microRNA pathways | |
| Katsushima et al. | Long non-coding RNAs in brain tumors | |
| Liu et al. | Cancer epigenetics and the potential of epigenetic drugs for treating solid tumors | |
| JP2018515130A5 (enExample) | ||
| JP2019510075A5 (enExample) | ||
| Krantz et al. | Pancreas adenocarcinoma: novel therapeutics | |
| Liu et al. | Trichostatin A promotes esophageal squamous cell carcinoma cell migration and EMT through BRD4/ERK1/2‐dependent pathway | |
| Peng et al. | Overexpression of miR-145 increases the sensitivity of vemurafenib in drug-resistant colo205 cell line | |
| Zhou et al. | Circular RNA-regulated autophagy is involved in cancer progression | |
| Yang et al. | Vessel co-option: A unique vascular-immune niche in liver cancer | |
| CN109328072B (zh) | 细胞死亡诱导剂、细胞增殖抑制剂及用于治疗起因于细胞增殖异常的疾病的医药组合物 | |
| Wang et al. | Therapeutic targeting of cGAS–STING pathway in lung cancer | |
| Nie et al. | The role of notch signaling pathway and non-coding RNAs in cancer and inflammation: progress, therapeutic insights, and future directions | |
| JP2016523961A5 (enExample) |